Lecture abstract:

Hyperbaric oxygen therapy (HBOT) is a dual-component therapy composed of increased barometric pressure and hyperoxia that have primary epigenetic effects. HBOT affects the expression and suppression of over 40% of the protein-coding genes in human chromosomes. Amongst the largest clusters of genes expressed and suppressed are the anti-inflammatory and pro-inflammatory genes, respectively. This talk will briefly review the definition and mechanisms of action of HBOT, the rationale for treating spike protein-induced diseases with HBOT, the literature on HBOT’s effects on inflammation/immune system dysfunction, and the literature on applying HBOT to spike-induced diseases. It will conclude with recommendations for treating spike-induced diseases with HBOT.

An Emergency Medicine and Hyperbaric Medicine clinician, Paul Harch is a Clinical Professor of Medicine, Section of Emergency Medicine, at LSU School of Medicine in New Orleans, and former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship.

In 1989, he adapted concepts of conventional hyperbaric oxygen therapy (HBOT) to treat and conduct research on patients with wounds in the central nervous system. That initiative resulted in a private practice with one of the largest and most diverse case experiences in neurological hyperbaric medicine in the world.

In March 2020, Dr. Harch proposed the use of HBOT to treat COVID-19 pneumonia based on similar and successful use in 1918 for patients dying of Spanish Flu. Dr. Harch has now successfully treated patients with long COVID-19 and COVID vaccine injuries.

His work and perspectives on hyperbaric oxygen therapy have been published in multiple scientific articles, book chapters, and in his book, “The Oxygen Revolution”, where HBOT is explained as an epigenetic therapy with expected revolutionary effects on medicine and neurology.